Among these, the S1R has emerged as a promising therapeutic target, and currently, both novel investigative and repurposed drugs targeting the S1R are being explored for their effect on diseases such as AD, PD, HD, and ALS [5,39,40,41]. Here, TMBIM4 is linked to Huntington disease.